Pfizer, Inc.
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Company detailsClinical calendar
Stock categories
Clinical calendar
- Aug 23, 2026EST.
PFEPhase 1/Phase 2OncologyActive Not Recruiting - Aug 28, 2026EST.
AZNPhase 1/Phase 2OncologyActive Not Recruiting AstraZeneca PLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Company details - Aug 30, 2026EST.
MRKPhase 2OncologyActive Not Recruiting Merck & Company, Inc.
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Company details - Sep 2026EST.
ABBVPhase 2OncologyActive Not Recruiting AbbVie Inc.
Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer
Company details - Sep 2026EST.
AZNPhase 1/Phase 2OncologyActive Not Recruiting AstraZeneca PLC
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Company details - Sep 2026EST.
AZNPhase 1/Phase 2OncologyRecruiting AstraZeneca PLC
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
Company details - Sep 2026EST.
AZNPhase 2OncologyActive Not Recruiting AstraZeneca PLC
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Company details - Sep 2026EST.
AZNPhase 2OncologyEnrolling By Invitation AstraZeneca PLC
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Company details - Sep 2026EST.
GILDPhase 2Infection & vaccinesActive Not Recruiting Gilead Sciences, Inc.
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
Company details - Sep 2026EST.
LLYPhase 2Diabetes & metabolicActive Not Recruiting Eli Lilly and Company
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Company details - Sep 2026EST.
MAZEPhase 2CardiovascularRecruiting Maze Therapeutics, Inc.
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
Company details - Sep 2026EST.
MRKPhase 2OncologyActive Not Recruiting Merck & Company, Inc.
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Company details - Sep 2026EST.
SNDXPhase 2OncologyActive Not Recruiting Syndax Pharmaceuticals, Inc.
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Company details - Sep 1, 2026EST.
NVOPhase 2Diabetes & metabolicRecruiting Novo Nordisk A/S
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Company details - Sep 1, 2026EST.
PFEPhase 1/Phase 2OncologyActive Not Recruiting Pfizer, Inc.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Company details - Sep 2, 2026EST.
MRKPhase 2OncologyActive Not Recruiting Merck & Company, Inc.
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Company details - Sep 5, 2026EST.
MRKPhase 2ImmunologyActive Not Recruiting Merck & Company, Inc.
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Company details - Sep 15, 2026EST.
PFEPhase 1/Phase 2Devices & healthcareRecruiting Pfizer, Inc.
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
Company details
